<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812355</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT n. 2016-001529-15</org_study_id>
    <nct_id>NCT02812355</nct_id>
  </id_info>
  <brief_title>Randomized Anticoagulation Trial in Opcab (RATIO)</brief_title>
  <acronym>RATIO</acronym>
  <official_title>High Dose Versus Low Dose Heparinization in Patients Undergoing Offpump Coronary Artery Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Lecco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera di Lecco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RATIO Study is a multicenter, nationwide, randomized, controlled, single blinded,
      unfunded trial of n. 900 patients undergoing multivessel OPCAB (≥2 grafts). This study is
      designed to test in patients undergoing off-pump coronary artery bypass surgery the
      hypothesis that full (high dose, 300 U/kg) and half (low dose,150 U/kg) heparinization are
      not different in terms of thrombotic complications and major perioperative bleeding events
      (null hypothesis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Off-pump coronary artery bypass grafting (OPCAB) is an established alternative to on-pump
      coronary artery bypass grafting (CABG). OPCAB determines a pro-coagulant state potentially
      deleterious on grafts patency, that is not counterbalanced by the adverse effects of
      cardiopulmonary bypass on coagulation occurring in CABG, and that lasts as long as one month.
      Therefore in OPCAB systemic heparinization is necessary to prevent thrombotic complications
      during transitory occlusion of coronary arteries and grafts. An internationally accepted
      standard intra-operative anticoagulation protocol for OPCAB has not yet been defined, and
      heparinization in OPCAB is a highly variable practice. The intraoperative anticoagulation
      regimen adopted in patients undergoing OPCAB may influence major postoperative outcomes, such
      as bleeding, transfusion requirements, inflammatory response, myocardial ischemia and grafts
      patency, but it has never been the object of large-scale randomized controlled trial (RCT).
      The 2 most widespread intraoperative anticoagulation protocols in OPCAB are represented by
      full (300 U/kg) or half (150 U/kg) heparinization, with target ACT ranging from 200 sec to
      &gt;480 sec.

      Patients enrolled in the study will be randomized to receive full or half heparinization in a
      1:1 ratio using a randomization schedule blocked by site. Randomization will take place in
      the operatory room by the anesthesiologist, and will be blinded to the surgeon.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite vascular</measure>
    <time_frame>30 days post-operatively</time_frame>
    <description>Death from vascular causes, perioperative myocardial infarction, stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite major bleeding</measure>
    <time_frame>48 hours post-operatively</time_frame>
    <description>Redo for excessive bleeding, cardiac tamponade, transfusion ≥3 Units of packed red cells or of platelets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative bleeding</measure>
    <time_frame>48 hours post-operatively</time_frame>
    <description>Total bleeding evaluated the morning after surgery (ml.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of packed red cells (&lt;3 Units) or of platelets</measure>
    <time_frame>30 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of cardiac biomarker</measure>
    <time_frame>30 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic cerebral attack</measure>
    <time_frame>30 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mesenteric ischemia (angiography or CT scan)</measure>
    <time_frame>30 days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolus (angiography or CT scan)</measure>
    <time_frame>30 days post-operatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>half heparinization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin I.V. 150 U/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>full heparinization (300 U/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>heparin I.V. 300 U/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>half heparinization</arm_group_label>
    <arm_group_label>full heparinization (300 U/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Consecutive patients electively undergoing multivessel OPCAB

        Exclusion Criteria:

        Acute coronary syndrome, on-going double anti-platelets treatment (the second antiplatelet
        drug should be suspended 5 days before surgery), on-going intravenous heparin or
        sub-cutaneous low molecular weight heparin, known coagulopathy, documented liver disease,
        chronic renal failure (creatinine ≥ 2 mg/dl) or previous renal transplantation surgery,
        previous cardiac surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele NR Triggiani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Lecco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele NR Triggiani, MD, PhD</last_name>
    <phone>+39-0341253066</phone>
    <email>m.triggiani@asst-lecco.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonello S Martino, MD</last_name>
    <phone>+39-0341253651</phone>
    <email>as.martino@asst-lecco.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jilin Heart Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Lemma, MD</last_name>
      <email>dr.lemma@jlheart.org</email>
    </contact>
    <investigator>
      <last_name>Massimo Lemma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Lecco</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Triggiani, MD, PhD</last_name>
      <phone>+390341253066</phone>
      <email>m.triggiani@asst-lecco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Massi, MD</last_name>
      <email>fmassi@aslsassari.it</email>
    </contact>
    <investigator>
      <last_name>Michele Portoghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Massi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ratiotrial.it</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Lecco</investigator_affiliation>
    <investigator_full_name>Michele Triggiani</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>off-pump</keyword>
  <keyword>coronary artery bypass</keyword>
  <keyword>heparinization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

